Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centro De Investigación Biomédica En Red is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The single pending matter reflects a concentrated prosecution effort in the pharmaceutical field.
The busiest examiner for the portfolio is BAKSHI, PANCHAM, who handles the 1 pending office action. This 1 matter represents the entirety of the organization's current pending prosecution. With 1 distinct examiner and 1 distinct art unit, the organization's patent strategy is currently subject to the review of a single individual. Practitioners should focus on the specific technical requirements of the Biotechnology & Pharmaceuticals unit, as there are no other pending matters to provide a broader view of the office's current stance on the organization's technology. The success of this portfolio depends on navigating the specific examination style of BAKSHI, PANCHAM.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAKSHI, PANCHAM | 1 | 76.7% | +30.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18652660 | TREATMENT OF MITOCHONDRIAL DISEASES | BAKSHI, PANCHAM | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18652660 | TREATMENT OF MITOCHONDRIAL DISEASES | BAKSHI, PANCHAM | 1623 | §102 | Final Rejection | — | Pending | May 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentro De Investigación Biomédica En Red has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Pancham Bakshi has the most, with 1 of Centro De Investigación Biomédica En Red's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.